Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
There are currently no approved disease-modifying therapies for MPS IIIA.
Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy
NMD Pharma to progress CMT pill despite primary endpoint miss
MHRA outlines upcoming IVD submission shift for clinical trials
Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial
Analysis
View More
Themes
View MoreOncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Massive Bio and ConcertAI revealed the AI oncology trial systems at SCOPE 2026.
More themes
Data Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View more
Digital Magazine
View MorePharma Technology Focus Magazine
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Patient-centric approaches thrive on wearables and remote access in trials
Pharma’s AI prospects get nudged into the future with EU’s AI act